Show simple item record

dc.contributor.advisorMomtaz, Tanisha
dc.contributor.authorAfrin, Sadia
dc.date.accessioned2024-10-27T09:39:25Z
dc.date.available2024-10-27T09:39:25Z
dc.date.copyright2022
dc.date.issued2022-02
dc.identifier.otherID 16346051
dc.identifier.urihttp://hdl.handle.net/10361/24408
dc.descriptionThis thesis is submitted in partial fulfilment of the requirements for the degree of Bachelor of Pharmacy, 2022.en_US
dc.descriptionCatalogued from PDF version of thesis.
dc.descriptionIncludes bibliographical references (pages 26-31).
dc.description.abstractTraditional treatments and symptomatic care are still the only options for most patients as no therapeutic drug has been licensed for treating COVID-19 yet. Monoclonal antibodies generated from convalescent patients or humanized mice exposed to SARS-CoV-2 antigens were awarded emergency use authorization. An ongoing phase I, II, and III placebo-controlled trial is testing whether symptomatic adults can be treated safely and effectively. Casirivimab and imdevimab may have a therapeutic benefit in people who were seronegative when they received treatment. An IgG1 (Immunoglobulin G1) with an unaltered Fc region, Bamlanivimab was generated from the convalescent plasma of a COVID-19 patient. Patients with renal impairment, pregnancy, or breastfeeding status are not advised to alter their dosages. SARS-genomic CoV-2's organization is nearly identical to that of SARS-CoV, with the exception of a few genes for accessory proteins.en_US
dc.description.statementofresponsibilitySadia Afrin
dc.format.extent31 pages
dc.language.isoenen_US
dc.publisherBrac Universityen_US
dc.rightsBRAC University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission.
dc.subjectCasirivimaben_US
dc.subjectImdevimaben_US
dc.subjectBamlanivimaben_US
dc.subjectSARS-CoV-2en_US
dc.subjectImmunoglobulin G1en_US
dc.subjectPlacebo-controlled trialen_US
dc.subject.lcshCovid 19--Treatment.
dc.titleA review on role of anti-SARS-CoV-2 monoclonal antibodies in the treatment of COVID-19en_US
dc.typeThesisen_US
dc.contributor.departmentDepartment of Pharmacy, BRAC University
dc.description.degreeB. Pharmacy


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record